Clinical validation Opportunity to engage hospitals and clinics with BreathBase as a non-invasive diagnostic tool. Their already active multi-centre prospective study suggests receptiveness to real-world evidence generation, which can support reimbursement discussions and standard-of-care integration.

Early detection Position BreathBase as a screening adjunct for chronic respiratory diseases, cancer, and infectious diseases. With AI-driven on-site analysis in seconds, there is potential for partnerships with healthcare providers seeking rapid, non-invasive triage and early intervention.

Data network Leverage Breathomix’s growing reference database and cloud platform to offer data-driven insights services, longitudinal biomarker tracking, and collaborative research opportunities with academic medical centers and biopharma.

Strategic partnerships Target collaborations with system integrators, medical device distributors, and Evalan-like technology partners to scale production, deployment, and field support for the BreathBase ecosystem.

Growth potential With modest revenue and a small team, there is room to propose pilot programs in dedicated care settings, integrate with Azure-based infrastructures, and pursue grants or co-development deals to accelerate market adoption.